News

The FDA has set a target action date of September 27, 2024, for a decision on the supplemental biologics license application of isatuximab plus bortezomib, lenalidomide, and dexamethasone.

In part 1 of our 3-part series, antibody-drug conjugates are revolutionizing oncology, targeting cancer cells precisely. Agents like T-DM1, T-DXd, and sacituzumab govitecan continue to change the field.

An interim analysis of the CheckMate 77T trial shows that nivolumab plus chemotherapy improves event-free survival in resectable non-small cell lung cancer vs chemotherapy alone.

Interim results show promising efficacy of palazestrant/ribociclib in ER+/HER2– metastatic breast cancer, an approval for tarlatamab-dlle, and data suggesting early ctDNA kinetics as a potential pharmacodynamic biomarker. We also cover the initiation of dosing quaratusugene ozeplasmid/atezolizumab in SCLC and more.

Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the specific patient subgroups for whom autologous transplant remains the best course of action for.

According to findings from a retrospective analysis, young adults under 40 years of age who received a human papillomavirus vaccination had lower rates of HPV-related cancer.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the background and findings from a study comparing patients who underwent thymectomy and nephrectomy.

A study offers promising news for young women with early-stage breast cancer who want to have children after treatment, showing that 73% of breast cancer survivors who attempted pregnancy were successful.

A study has shown artificial intelligence virtual navigation to be a promising tool to improve colonoscopy completion rates, with high patient acceptance.

CEE therapy alone in postmenopausal women after hysterectomy was linked to a substantial increase in ovarian cancer incidence and mortality.

VCN-01, an adenovirus therapy, received fast track designation from the FDA for treating metastatic pancreatic cancer in combination with standard chemotherapy.

The protocol for a phase 3 clinical trial testing a new combination therapy targeting advanced prostate cancer has received approval from the FDA.

The May 2024 ODAC meeting discussed FDARA's impact on pediatric cancer drug development, emphasizing international collaboration and early regulatory engagement.

Targeted Oncology spoke with Howard D. Edington, MD, about how experts are addressing the potential of resistance challenges with oncolytic viruses as part of its Speaking Out video series.

In an interview with Targeted Oncology, Joe Leach, MD, highlighted the current state and future prospects of treating patients with small cell lung cancer.

Change Healthcare, owned by UnitedHealth Group, was targeted by cybercriminals, affecting 140 million Americans and costing $1 billion daily. Recovery efforts underscore the critical need for robust cybersecurity measures in healthcare.

Kim N. Chi, MD, FRCPC, discusses how the findings from the phase 3 MAGNITUDE trial translate into everyday practice.

RAG-01 has received an FDA fast track designation and is being investigated for the treatment of non-muscle invasive bladder cancer.

Nini Wu, MD, MBA, highlights practical technology in community oncology and how it is used to enhance patient and staff experiences.

Data from the phase 3 INAVO120 trial support the breakthrough therapy designation granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of PIK3CA-mutated breast cancer.

Gabriel N. Hortabagyi, MD, FACP, provides an overview of the phase 3 NATALEE trial evaluating the combination of ribociclib with endocrine therapy as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer.

The first patient has been given CT-0525, a first-in-class, ex vivo gene-modified autologous CAR-monocyte cellular therapy, in a phase 1 trial of the agent for those with HER2-overexpressing solid tumors.

The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted.

Topline findings from the KICKSTART study showed that tomivosertib led to modest activity in non-small cell lung cancer (NSCLC).

A study found that a novel ointment improved symptoms in patients with cutaneous T-cell lymphoma. The treatment was well-tolerated with minimal adverse effects.

Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.

Trials in small cell lung cancer and non–small cell lung cancer are fueling excitement in the oncology community.

Experts explore challenges in brain tumor management, and nivolumab/ipilimumab fails to improve PFS in NSCLC. We also cover access to 177Lutetium-PSMA-617, developments in mRNA cancer vaccine WGc-043, and antibody-drug conjugate 9MW2821 in esophageal cancer.

Pembrolizumab with chemotherapy led to a positive trend in overall survival among patients with endometrial cancer.